natgillin/translations-raw huggingface dataset:
• The purpose of the setup is to make sure that your Byettapen is ready to use for the next 30 days.
• Namen priprave je zagotovitev, da je vaš injekcijski peresnik Byetta pripravljen za odmerjanje za naslednjih 30 dni.
• itching (with or without rash)
• srbenje (z ali brez izpuščaja)
Your doctor is now prescribing Byetta as an additional medicine to help control your blood sugar.
Vaš zdravnik vam je predpisal zdravilo Byetta kot dodatno zdravilo, ki vam bo pomagalo nadzorovati vrednosti vašega sladkorja v krvi.
- If you have ever had inflammation of the pancreas (pancreatitis) (see section 4).
- Če ste kdaj imeli vnetje trebušne slinavke (pankreatitis) (glejte poglavje 4).
Severe allergic reactions (anaphylaxis) have been reported rarely (may affect up to 1 in 1,000 people).
Redko so poročali o hudih alergijskih reakcijah (anafilaksija) (pojavijo se lahko pri največ 1 od 1.000 bolnikov).
Back
Zadaj
Exenatide has not been studied in patients with severe gastrointestinal disease, including gastroparesis.
Uporabe eksenatida niso preučevali pri bolnikih s hudo boleznijo prebavil, vključno z gastroparezo.
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines, particularly: - medicines that are used to treat type 2 diabetes that work like Byetta (e.g. liraglutide and prolonged-release exenatide), as taking these medicines with Byetta is not recommended.
Obvestite zdravnika ali farmacevta, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katero koli drugo zdravilo, še posebno: - zdravila, ki se uporabljajo za zdravljenje sladkorne bolezni tipa 2, ki delujejo tako kot zdravilo Byetta (npr. liraglutid in eksenatid v obliki s podaljšanim sproščanjem), ker se jemanje teh zdravil z zdravilom Byetta ne priporoča.
The signs and symptoms of low blood sugar may include headache, drowsiness, weakness, dizziness, confusion, irritability, hunger, fast heartbeat, sweating, and feeling jittery.
Znaki in simptomi nizkega sladkorja v krvi lahko vključujejo glavobol, zaspanost, slabotnost, omotičnost, zmedenost, razdražljivost, lakoto, hitro bitje srca, znojenje in občutek živčnosti.
What should I do if Byetta does not come out of the needle tip after four tries during New Pen Setup?
Kaj naj storim, če zdravilo Byetta ne priteče iz konice igle po štirih poskusih priprave novega injekcijskega peresnika?
Fertility No fertility studies in humans have been conducted.
Plodnost Študij plodnosti na ljudeh niso izvedli.
CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT
VSEBINA, IZRAŽENA S MASO, PROSTORNINO ALI ŠTEVILOM ENOT
Metformin or sulphonylureas
Metformin in sulfonilsečnine
60 doses (1.2 ml)
60 odmerkov (1,2 ml)
• Healthcare professionals or other caregivers should follow local or institutional policies regarding needle handling.
• Zdravstveni delavci ali drugo negovalno osebje mora glede ravnanja z iglami slediti lokalnim smernicam ali smernicam ustanov.
Do not throw away.
Ne zavrzite je.
Your doctor or nurse must teach you how to inject Byetta before you use it for the first time.
Vaš zdravnik ali medicinska sestra vas morata pred prvo uporabo poučiti o tem, kako si injicirati zdravilo Byetta.
• Go to Section 3, Step 3, for instructions on how to inject your first routine dose.
• Pojdite na Poglavje 3, Korak 3 za navodila glede injiciranja vašega prvega odmerka pri vsakodnevni uporabi.
You should inject this medicine at any time within the 60 minutes (1 hour) before your morning and evening meals, or before your two main meals of the day, which should be about 6 hours or more apart.
To zdravilo si morate injicirati kadarkoli v roku 60 minut (1 ure) pred vašim jutranjim in večernim obrokom ali pred dvema vašima glavnima dnevnima obrokoma, ki naj bosta časovno približno 6 ur ali več narazen.
Rate based on immediate-release exenatide completed long-term efficacy and safety studies n=5763 total (patients on sulphonylurea n=2971).
Pogostnost na podlagi dokončanih dolgoročnih študij učinkovitosti in varnosti eksenatida v obliki s takojšnjim sproščanjem, n skupaj = 5763, (število bolnikov na sulfonilsečnini n = 2971).
For instructions for using the pen, see section 6.6 and the user manual included with the leaflet.
Za navodila o uporabi injekcijskega peresnika glejte poglavje 6.6 in navodila, ki so priložena navodilu za uporabo.
• Follow the instructions for hygienic injection technique recommended by your healthcare professional.
• Sledite navodilom o higienski tehniki injiciranja, ki jo priporoča vaš zdravstveni delavec.
If such medicinal products are to be administered with food, patients should be advised to, if possible, take them with a meal when immediate-release exenatide is not administered.
Če se ta zdravila jemljejo s hrano, moramo bolnikom svetovati, da jih, če je mogoče, vzamejo med obrokom, ko ne vzamejo eksenatida v obliki s takojšnjim sproščanjem.
If you are using insulin, your doctor will tell you how to reduce the dose of insulin and will recommend that you monitor your blood sugar more frequently, in order to avoid hyperglycaemia (high blood sugar) and diabetic ketoacidosis (a complication of diabetes that occurs when the body is unable to break down glucose because there is not enough insulin).
Če uporabljate insulin, vam bo zdravnik povedal, kako zmanjšate odmerek insulina, in priporočil pogostejše spremljanje sladkorja, da s tem preprečite pojav hiperglikemije (visoka raven sladkorja v krvi) in diabetične ketoacidoze (zaplet pri sladkorni bolezni, ki nastopi, ko telo zaradi pomanjkanja insulina ni sposobno razgraditi glukoze).
(See Storing Your ByettaPenin Section 1 of this user manual for more information.)
(Za več informacij glejte Shranjevanje vašega injekcijskega peresnika Byetta v Poglavju 1 tega Priročnika za uporabo.)
If you use more Byetta than you should
Če ste uporabili večji odmerek zdravila Byetta, kot bi smeli
Overall, the percentage of antibody positive patients was consistent across clinical trials.
Celostno je bil odstotek bolnikov s pozitivnimi protitelesi v kliničnih preskušanjih podoben.
• dehydration, generally associated with nausea, vomiting and/or diarrhoea
• dehidracija, običajno pridružena slabosti, bruhanju in/ali driski
Exenatide has been shown to bind to and activate the known human GLP-1 receptor in vitro, its mechanism of action mediated by cyclic AMP and/or other intracellular signalling pathways.
Pokazali so, da se eksenatid in vitro veže na in aktivira znani humani receptor GLP-1, katerega mehanizem delovanja posreduje ciklični AMP in/ali druge znotrajcelične poti sporočanja.
In the three placebo-controlled trials (n=963) 38% of patients had low titre anti-exenatide antibodies at 30 weeks.
V treh s placebom nadzorovanih preskušanjih (n=963) je imelo 38 % bolnikov po 30 tednih nizke titre protiteles proti eksenatidu.
This incidence was not statistically significant when adjusted for survival.
Ta incidenca pri prilagoditvi za preživetje ni bila statistično značilna.
Failure to follow these instructions completely may result in a wrong dose, a broken pen or an infection.
Neupoštevanje teh navodil lahko povzroči nepravilno odmerjanje zdravila, lahko pride do poškodbe injekcijskega peresnika ali infekcije.
• The cartridge in your Byetta pen may not have enough liquid to deliver a full dose.
• Vložek vašega injekcijskega peresnika Byetta morda ne vsebuje zadosti tekočine za dajanje celotnega odmerka.
Signs and symptoms of overdose may include severe nausea, severe vomiting and rapidly declining blood glucose concentrations.
Znaki in simptomi prevelikega odmerjanja lahko vključujejo hudo navzeo, hudo bruhanje in hitro padanje koncentracije glukoze v krvi.
Exenatide should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis.
Eksenatida v obliki s takojšnjim sproščanjem ne smemo uporabljati pri bolnikih z diabetesom mellitusom tipa 1 ali za zdravljenje diabetične ketoacidoze.
- medicines used to thin the blood (anticoagulants), e.g. warfarin, as you will require additional monitoring of changes in INR (measurement of blood thinning) during initiation of therapy with this medicine.
- zdravila, ki se uporabljajo za redčenje krvi (antikoagulanti), npr. varfarin, ker boste na začetku zdravljenja s tem zdravilom potrebovali dodatno kontroliranje sprememb INR (INR je mera za redčenje krvi).
Use a new injection needle for each injection and dispose of it after each use.
Za vsako injiciranje uporabite novo injekcijsko iglo in jo po vsaki uporabi zavrzite.
After using Byetta 5 micrograms twice a day for 30 days the doctor may increase your dose to Byetta 10 micrograms twice a day.
Po uporabi zdravila Byetta 5 mikrogramov (µg) 30 dni dvakrat na dan, lahko zdravnik poveča vaš odmerek na zdravilo Byetta 10 mikrogramov (µg) dvakrat na dan.
Injection needles are not included.
Igle za injiciranje niso vključene.
This symbol means the dose knob is pushed in and the pen is ready to reset.
Ta simbol pomeni, da je gumb za odmerjanje pritisnjen ter, da je injekcijski peresnik pripravljen za ponovno nastavitev.
These reactions have usually been mild and usually did not result in discontinuation of immediate-release exenatide.
Te reakcije so bile navadno blage in po navadi niso povzročile prekinitve zdravljenja z eksenatidom v obliki s takojšnjim sproščanjem.
If the cartridge contains a small amount or looks empty, obtain a new Byetta pen.
Če vložek vsebuje malo tekočine ali izgleda prazen, si priskrbite nov injekcijski peresnik Byetta.
• Changes in INR (measurement of blood thinning) have been reported when used together with warfarin.
• spremembe INR (merilo za gostoto krvi) ob sočasni uporabi z varfarinom.
Blood glucose self-monitoring is necessary to adjust the dose of sulphonylurea or insulin, particularly when Byetta therapy is started and insulin is reduced.
Bolnikov samonadzor glukoze v krvi pa je potreben za prilagajanje odmerka sulfonilsečnine ali insulina, zlasti ob začetku zdravljenja z zdravilom Byetta in zmanjšanju odmerka insulina.
Mannitol, glacial acetic acid, sodium acetate trihydrate, water for injections.
Manitol, ledocetna kislina, natrijev acetat trihidrat, voda za injekcije.
Concomitant medicinal products included angiotensin converting enzymes inhibitors, angiotensin-II antagonists, nonsteroidal anti-inflammatory medicinal products and diuretics.
Sočasno uporabljena zdravila vključujejo zaviralce angiotenzinske konvertaze, antagoniste angiotenzina II, nesteroidna protivnetna zdravila in diuretike.
In clinical studies the mean apparent clearance of exenatide is 9 l/h and the mean terminal half-life is 2.4 h. These pharmacokinetic characteristics of exenatide are independent of the dose.
V kliničnih študijah je povprečni opaženi očistek eksenatida 9 l/h in povprečni končni razpolovni čas 2,4 h. Te farmakokinetične značilnosti eksenatida so neodvisne od odmerka.
To reduce the risk of hypoglycaemia associated with the use of a sulphonylurea, reduction in the dose of sulphonylurea should be considered.
Za zmanjšanje tveganja za hipoglikemijo, povezano z uporabo sulfonilsečnine, je potrebno premisliti o zmanjšanju odmerka sulfonilsečnine.
When exenatide was used in combination with metformin alone, no increase in the incidence of hypoglycaemia was observed over that of placebo in combination with metformin which may be due to this glucose-dependent insulinotropic mechanism (see section 4.4).
Ko so eksenatid uporabljali v kombinaciji samo z metforminom, niso opazili povečanja incidence hipoglikemije glede na placebo v kombinaciji z metforminom, kar je lahko zaradi tega od glukoze odvisnega insulinotropnega mehanizma (glejte poglavje 4.4).
Note: A small air bubble in the cartridge is normal
Opomba: Majhen zračni mehurček v vložku je običajen.
• Rashes, itching and rapid swelling of the tissues of the neck, face, mouth orthroat
• izpuščaji, srbenje in hitro otekanje tkiv v vratu, na obrazu, v ustih ali v žrelu
- If you lose weight too quickly (more than 1.5 kg per week) talk to your doctor about it since this may cause problems such as gallstones.
- Če prehitro izgubljate telesno maso (več kot 1,5 kg na teden), se o tem posvetujte z zdravnikom, ker lahko to povzroči težave kot npr. žolčne kamne.
A small amount of Byetta will always remain in the cartridge.
Majhna količina zdravila Byetta bo vedno ostala v vložku.
Clearance was significantly reduced by 84% in patients with end-stage renal disease receiving dialysis (see section 4.2).
Očistek se je značilno zmanjšal za 84 % pri bolnikih s končno stopnjo bolezni ledvic na dializi (glejte poglavje 4.2).
Consistent with the potentially immunogenic properties of protein and peptide pharmaceuticals, patients may develop anti-exenatide antibodies following treatment with immediate-release exenatide.
V skladu z morebitno imunogenimi lastnostmi beljakovinskih in peptidnih zdravilnih učinkovin, lahko bolniki po zdravljenju z eksenatidom v obliki s takojšnjim sproščanjem razvijejo protitelesa proti eksenatidu.
Do not use this medicine after the expiry date, which is stated on the label and the carton after ‘EXP'.
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na nalepki in škatli poleg oznake 'EXP'.
STEP 6 Remove and Dispose of the Needle
KORAK 6 Odstranite in zavrzite iglo
Administration of exenatide has been shown to reduce food intake, due to decreased appetite and increased satiety.
Pokazali so, da dajanje eksenatida zmanjša vnos hrane zaradi zmanjšanega apetita in povečanja občutka sitosti.
Immediate-release exenatide has shown no adverse effects on lipid parameters.
Eksenatid v obliki s takojšnjim sproščanjem ni pokazalo neželenih učinkov na maščobne parametre.
One injection of your pre-filled pen will give you your dose.
Z eno injekcijo vašega napolnjenega injekcijskega peresnika boste dobili vaš odmerek.
If you are having problems using your Byetta pen, contact your healthcare professional.
Če imate težave z uporabo vašega injekcijskega peresnika Byetta, se obrnite na zdravstvenega delavca.
For oral medicinal products that are particularly dependent on threshold concentrations for efficacy, such as antibiotics, patients should be advised to take those medicinal products at least 1 hour before immediate-release exenatide injection.
Za peroralna zdravila, katerih učinkovitost je zlasti odvisna od mejnih koncentracij, kot so antibiotiki, moramo bolnikom svetovati, da ta zdravila vzamejo najmanj 1 uro pred injiciranjem eksenatida v obliki s takojšnjim sproščanjem.
The mean apparent volume of distribution of exenatide following subcutaneous administration of a single dose of exenatide is 28 l.
Povprečna opažena prostornina porazdelitve eksenatida po subkutanem dajanju enkratnega odmerka eksenatida je 28 l.
• The liquid should be clear, colourless, and free of particles.
• Tekočina mora biti bistra, brezbarvna in brez delcev.
Help will be needed by a person trained to use the pen.
Te osebe potrebujejo pomoč osebe, usposobljene za uporabo injekcijskega peresnika.
• Never push the injection button on the pen unless a needle is attached.
• Nikoli ne pritisnite gumba za injiciranje injekcijskega peresnika, razen če je pritrjena igla.
The most common adverse events leading to withdrawal for immediate-release exenatide-treated patients were nausea (4% of patients) and vomiting (1%).
Najpogostejša neželena učinka, ki sta vodila v prekinitev pri bolnikih zdravljenih z eksenatidom v obliki s takojšnjim sproščanjem, sta bila navzea (4 % bolnikov) in bruhanje (1 %).
Becton, Dickinson and Company needles are suitable to use with the Byetta pen.
Igle proizvajalca Becton, Dickinson and Company so primerne za uporabo z injekcijskim peresnikom Byetta.
Both treatment arms were titrated to achieve target fasting plasma glucose levels (see section 5.1).
Obe veji zdravljenja sta bili titrirani za dosego ciljnih nivojev glukoze v krvi na tešče (glejte poglavje 5.1).
• If needed, wipe the outside of the pen with a clean, damp cloth.
• Če je potrebno, obrišite zunanjost injekcijskega peresnika s čisto, vlažno krpo.
Do I use a new needle for each injection?
Ali naj za vsako injiciranje uporabim novo iglo?
Exenatide exposure increased proportionally over the therapeutic dose range of 5 mcg to 10 mcg.
Izpostavljenost eksenatidu se je povečevala sorazmerno v razponu terapevtskih odmerkov od 5 μg do 10 μg.
The reduction in Cmax is of limited clinical relevance and no adjustment of dosing of oral contraceptives is required.
Znižanje Cmax ima omejeno klinično vrednost, zato prilagoditev odmerjanja peroralnih kontraceptivov ni potrebna.
Do not use this medicine if you notice particles in the solution, or if it is cloudy or coloured.
Tega zdravila ne uporabljajte, če v raztopini opazite delce ali je raztopina motna ali obarvana.
Check the symbol in the dose window.
Preverite oznako v okencu za odmerjanje.
Neonatal growth was reduced in mice exposed to high doses during late gestation and lactation.
Rast novorojenca je bila manjša pri miših izpostavljenih visokim odmerkom med pozno gestacijo in dojenjem.
The concurrent use of immediate-release exenatide with D-phenylalanine derivatives (meglitinides), alpha-glucosidase inhibitors, dipeptidyl peptidase-4 inhibitors or other GLP-1 receptor agonists has not been studied and cannot be recommended.
Sočasne uporabe eksenatida v obliki s takojšnjim sproščanjem z derivati D-fenilalanina (meglitinidi), zaviralci alfa-glukozidaze, zaviralci dipeptidil peptidaze-4 ali drugimi agonisti receptorja GLP-1 niso preučevali in je ne priporočamo.
C.OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION
C. DRUGI POGOJI IN ZAHTEVE DOVOLJENJA ZA PROMET Z ZDRAVILOM
High doses of exenatide during mid-gestation caused skeletal effects and reduced foetal growth in mice and reduced foetal growth in rabbits.
Visoki odmerki eksenatida med srednjo gestacijo so povzročili učinke na okostju in manjšo rast ploda pri miših ter manjšo rast ploda pri kuncih.
The liquid should be clear, colourless, and free of particles.
Tekočina mora biti bistra, brezbarvna in brez delcev.
Hypoglycaemia was reported in 11% and 7% of patients treated with exenatide and placebo respectively.
O hipoglikemiji so poročali pri 11 % in 7 % bolnikov, zdravljenih z eksenatidom oziroma placebom.
Immediate-release exenatide is not expected to have any clinically relevant effects on the pharmacokinetics of metformin or sulphonylureas.
Ne pričakujemo, da bi eksenatid v obliki s takojšnjim sproščanjem imel klinično pomembne učinke na farmakokinetiko metformina ali sulfonilsečnin.
There is little experience with this medicine in patients with kidney problems
Malo je izkušenj z uporabo tega zdravila pri bolnikih, ki imajo težave z ledvicami.
Excipients This medicinal product contains metacresol, which may cause allergic reactions.
Pomožne snovi To zdravilo vsebuje metakrezol, ki lahko povzroča alergijske reakcije.
Set up your new pen just before you use it for the first time.
Vaš novi injekcijski peresnik pripravite tik preden ga boste prvič uporabili.
A pharmacodynamic study demonstrated in patients with type 2 diabetes (n=13) a restoration of first phase insulin secretion and improved second phase insulin secretion in response to an intravenous bolus of glucose.
Farmakodinamična študija je pri bolnikih z diabetesom tipa 2 (n=13) pokazala obnovo prve faze izločanja insulina in izboljšanje druge faze izločanja insulina kot odgovor na intravenski bolus glukoze.
Date of first use Date to throw away pen
Datum prve uporabe Datum, ko boste zavrgli injekcijski peresnik
• To prevent this, for your next dose, firmly push and hold the injection button in and slowly count to 5 (see Section 3, Step 4: Inject the Dose).
• Da to preprečite, pri naslednjem odmerku čvrsto pritisnite in držite gumb za injiciranje ter počasi štejete do 5 (glejte Poglavje 3, Korak 4: Injicirajte odmerek).
Immediate-release exenatide can be administered at any time within the 60-minute period before the morning and evening meal (or two main meals of the day, approximately 6 hours or more apart).
Eksenatid v obliki s takojšnjim sproščanjem lahko damo kadarkoli v roku 60-minut pred jutranjim in večernim obrokom (ali dvema glavnima dnevnima obrokoma, ki sta približno 6 ur ali več narazen).
Long-term controlled data in elderly are limited, but suggest no marked changes in exenatide exposure with increased age up to about 75 years old.
Podatki o dolgotrajni nadzorovani uporabi pri starejših so omejeni, vendar z večanjem starosti vse do približno 75 leta starosti ne kažejo izrazitih sprememb v izpostavitvi eksenatidu.
Exenatide is cleared primarily by the kidney, therefore hepatic dysfunction is not expected to affect blood concentrations of exenatide.
Eksenatid se izloča zlasti preko ledvic, zato ne pričakujemo, da bi okvara jeter vplivala na koncentracije eksenatida v krvi.
• Section 3 of this manual should be used for every injection.
• Uporabite Poglavje 3 teh navodil pri vsakem injiciranju.
• If you repeat the New Pen Setup before each routine dose, you will not have enough Byetta for 30 days.
• Če pred vsakim rednim odmerjanjem ponovite pripravo novega injekcijskega peresnika, ne boste imeli dovolj zdravila Byetta za 30 dni.
The reduction in HbA1c was sustained and the weight loss continued for at least 82 weeks in the subset of 10 mcg BID patients completing both the placebo-controlled studies and the uncontrolled study extensions (n=137).
Zmanjšanje HbA1c je bilo trajno in zmanjševanje telesne mase se je nadaljevalo najmanj 82 tednov pri skupini bolnikov z 10 μg dvakrat na dan, ki so dokončali podaljšanja tako s placebom nadzorovanih kot nenadzorovanih študij (n=137).
It is not known if exenatide passes into your milk.
Ni znano ali eksenatid prehaja v materino mleko.
For routine use, do not repeat the New Pen Setup.
Za vsakodnevno uporabo, ne ponavljajte Priprave novega injekcijskega peresnika.
STEP 4 Inject the Dose
KORAK 4 Injicirajte odmerek
Ethinyl estradiol and levonorgestrel
Etinilestradiol in levonorgestrel
Administration of the oral contraceptive 30 minutes after immediate-release exenatide did not affect AUC but resulted in a reduction of the Cmax of ethinyl estradiol by 45%, and Cmax of levonorgestrel by 27-41%, and a delay in tmax by 2-4 h due to delayed gastric emptying.
Dajanje peroralnega kontraceptiva 30 minut po dajanju eksenatida v obliki s takojšnjim sproščanjem ni vplivalo na AUC, vendar je povzročilo znižanje Cmax etinildiestrola za 45 % in Cmax levonorgestrela za 27-41 % na zakasnitev tmax za 2-4 ure zaradi upočasnjenega praznjenja želodca.
- If you have severe kidney disease or you are on dialysis, as the use of this medicine is not recommended.
- Če imate hudo bolezen ledvic ali ste na dializi, ker se uporabe tega zdravila v tem primeru ne priporoča.
When exenatide is used in combination with a sulphonylurea or a basal insulin, patients should be advised to take precautions to avoid hypoglycaemia while driving and using machines.
Kadar eksenatid uporabljamo v kombinaciji s sulfonilsečnino ali bazalnim insulinom, moramo bolnikom svetovati o previdnostnih ukrepih, da bi se med vožnjo in upravljanjem s stroji izognili hipoglikemiji.
It is an injectable medicine used to improve blood sugar control in adults with type 2 (non-insulin dependent) diabetes mellitus.
To je zdravilo za injiciranje, ki ga uporabljamo za izboljšanje nadzora sladkorja v krvi pri odraslih s sladkorno boleznijo tipa 2 (od insulina neodvisno).
Rare side effects (may affect up to 1 in 1,000 people): • intestinal obstruction (blockage in intestine)
Redki neželeni učinki (pojavijo se lahko pri največ 1 od 1.000 bolnikov): • zapora črevesa (blokada v črevesu)
If you lose weight too quickly (more than 1.5 kg per week) talk to your doctor about it since this may cause problems such as gallstones.
Če telesno maso izgubljate prehitro (več kot 1,5 kg na teden), se pogovorite s svojim zdravnikom, saj to lahko povzroči težave z žolčnimi kamni.
What you need to know before you use Byetta
Kaj morate vedeti, preden boste uporabili zdravilo Byetta
− For tablets that you need to take with food, it may be best if they are taken at a meal at a time when this medicine is not being administered.
- tablete, ki jih morate vzeti s hrano, je morda najbolje, da jih vzamete med obrokom, v času ko ne uporabite zdravila Byetta.
• Check that the is in the dose window.
• Preverite, ali je v okencu za odmerjanje .